ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P grew its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 11.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 194,185 shares of the specialty pharmaceutical company's stock after purchasing an additional 19,568 shares during the quarter. Loomis Sayles & Co. L P owned approximately 0.92% of ANI Pharmaceuticals worth $10,735,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE raised its holdings in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares during the period. KBC Group NV increased its stake in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth $166,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after buying an additional 579 shares during the period. Finally, HighTower Advisors LLC acquired a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth approximately $222,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ANIP shares. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. Guggenheim raised their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Leerink Partnrs upgraded ANI Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, December 11th. Finally, Leerink Partners started coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $79.75.

ANI Pharmaceuticals Trading Down 2.9 %

ANIP stock traded down $2.01 during midday trading on Thursday, hitting $67.35. The stock had a trading volume of 43,502 shares, compared to its average volume of 256,828. The company's 50-day moving average price is $61.08 and its 200 day moving average price is $58.64. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a market cap of $1.47 billion, a PE ratio of -122.45 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.00.

Insider Activity

In other news, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,200 shares of company stock valued at $191,776 in the last 90 days. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.